The 2025 Revolutionizing Atopic Dermatitis meeting, held in Nashville, TN, has officially come and gone. Patient Care® editors covered several sessions, poster abstracts, and late-breaking data from the meeting, and interviewed multiple presenting authors and experts in the field of dermatology.

Below, we recap our complete coverage from the meeting, with direct links to our full articles, video interviews, and Q+A discussions with presenting authors.

Articles

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Final results from the phase 3b ADmirable trial showed lebrikizumab provided substantial improvements in skin clearance, itch reduction, and quality of life in patients with moderate-to-severe atopic dermatitis (AD) and skin of color, with a favorable safety profile through 24 weeks. In addition to improvements in disease severity and symptoms, lebrikizumab also reduced pigmentary sequelae, a common concern in patients with skin of color. Among patients with baseline hyperpigmentation (n = 52), 64% showed improvement by week 24. Of those with baseline hypopigmentation (n = 16), 25% improved. Few patients transitioned from one pigmentary change to another.

Click here for the full article

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis

Long-term results from the INTEGUMENT-OLE study demonstrated sustained improvements in signs, symptoms, and quality of life in participants aged ≥2 years with AD treated with once-daily or twice-weekly roflumilast (Zoryve) cream.

The phase 3, multicenter, open-label extension (OLE) enrolled 1220 participants from prior pivotal INTEGUMENT trials: INTEGUMENT-1/2 (participants aged ≥6 years; n = 658) and INTEGUMENT-PED (participants aged 2–5 years; n = 562). Participants who completed the 4-week parent trials without safety concerns received roflumilast cream 0.15% (≥6 years) or 0.05% (2–5 years) for up to 52 weeks. At week 56, Investigator Global Assessment for AD (vIGA-AD) scores of 0/1 (clear or almost clear) were achieved by 55.7% of participants aged ≥6 years and 63.1% of participants aged 2–5 years. A more than 2-point vIGA-AD improvement from baseline (vIGA-AD success) was achieved in 49.0% and 54.2% of the older and younger groups, respectively.

Click here for the full article

Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care

A real-world analysis of nearly 2000 patients with AD revealed a significant treatment gap, with only 8.61% of participants with moderate-to-severe disease using systemic therapies despite clinical guidelines recommending these medications for more severe cases. The findings revealed concerning patterns in treatment utilization. Among participants with mild disease, 91.39% used non-systemic treatments while 8.61% used systemic therapies. Surprisingly, those with moderate-to-severe disease showed nearly identical patterns, with 92.13% using non-systemic treatments and only 7.87% using systemic options. Investigators observed similar trends when examining itch intensity, with participants with high pruritis scores showing systemic treatment usage rates of just 7.87%.

Click here for the full article

Expert Interviews

Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD

"If there’s one thing I hope clinicians take away, it’s this: When a patient with AD walks into your clinic, it might feel like just another rash on the schedule. But for them, it could be the reason they don’t leave the house," expert dermatologist Mona Shahriari, MD, said to Patient Care editors at the conference. Shahriari is an assistant clinical professor of dermatology at Yale University School of Medicine in New Haven, CT and co-founder of Central Connecticut Dermatology in Cromwell, CT.

Click here for the full interview.

Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Johann Gudjonsson, MD, PhD, talked with Patient Care editors on his presentation exploring the OX-40/OX-40L signaling pathway and its central role in the pathogenesis of atopic dermatitis. In the interview, Gudjonsson, the Arthur C Curtis professor of skin molecular immunology at the University of Michigan, expanded on the genetic underpinnings of the OX-40 axis, its role in immune system activation, and why it is an increasingly important therapeutic target. He also discussed emerging treatment strategies, including combination approaches.

Click here for the full interview.

Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD

"This is critical: oral antihistamines are essentially ineffective for the itch of atopic dermatitis; perhaps the sedating ones can be helpful with sleep, but the mechanism of itch in AD does not involve histamine," Gil Yosipovitch, MD, professor of dermatology, the Stifel Endowed Chair of medical dermatology, and the director of the Miami Itch Center at the Doctor Philip Frost Department of Dermatology at the Miller School of Medicine in Miami, said at the start of his presentation. In an interview at the meeting with Patient Care,^© Yosipovitch highlighted the main areas of the presentation keeping in mind the interests of primary care clinicians who are the first practitioners in most cases to see a patient with a flare of the disease and to initiate treatment.

Click here for the full interview.

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Janus kinase (JAK) inhibitors provide rapid efficacy in the management of atopic dermatitis (AD) but present safety concerns for some heath care professionals because of the FDA black box warning across the class, a high-level precaution required following clinical trials of tofacitinib in rheumatoid arthritis. In an interview with Patient Care, Leon Kircik, MD, clarified misconceptions around the boxed warning, placing the caution in context and then shared his excitement about the "very rich pipeline in atopic dermatitis." Kircik is the founder and medical director of DermResearch and Physicians Skin Care, both in Louisville, as well as clinical professor of dermatology at Indiana University Medical Center in Indianapolis and at the Icahn School of Medicine in New York City.

Click here for the full interview.

Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis

Pediatric dermatologist Lisa Swanson, MD, joined allergist Anne Marie Singh, MD, for a collaborative presentation exploring clinical cross-talk between their specialties in the management of pediatric atopic dermatitis (AD). In an interview with Patient Care Online, Swanson previews their unique Q&A-style session, which aims to dispel common misconceptions around food allergy as a driver of eczema and to highlight significant advances in nonsteroidal and systemic therapies.

Click here for the full interview.

A Close Look at Flexible Dosing Strategies for Atopic Dermatitis in Adults with Raj Chovatiya, MD, PhD, MSCI

Raj Chovatiya, MD, PhD, MSCI, clinical associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology + Immunology Research in Chicago, reviewed dosing flexibility in adults with AD, highlighting potential regimen changes for injectable biologic therapies, and oral and topical therapies. Flexibility in use is based on both anecdotal real-world patterns and a growing body of clinical trial data, explained Chovatiya.

Click here for the full interview.

Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025

Jiade Yu, MD, director of the Contact Dermatitis Clinic at Massachusetts General Hospital, shared expert insights on chronic hand eczema (CHE)—a condition often mischaracterized and undertreated. Yu discussed how CHE differs from AD, the real-world burden it places on patients, and advances in treatment that may soon improve care. In our 4-part video series, each segment captured one key question and response from the interview, offering concise and clinically relevant takeaways for physicians managing chronic inflammatory skin conditions.

Click here for the full interview.

Pediatric Atopic Dermatitis: Navigating Patient, Provider, Caregiver Connection with Peter Lio, MD

Peter Lio, MD, assistant clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL, spoke to Patient Care editors on the connection between the patient, provider, and caregiver when seeing children with AD. His presentation touched on shared decision-making, the role of alternative medicine for AD treatment, and personalized medication plans.

Click here for the full interview.

For other highlights and exclusive expert interviews, check out our full meeting coverage of RAD 2025 here.